Dirigeants et représentants réglementaires de Pharma Labs s.r.l.
DI PILLO Roberto
(a) the conformity of the devices is appropriately checked, in accordance with the quality management system;
(b) the technical documentation and the EU declaration of conformity are drawn up and kept up-to-date;
(c) the post-market surveillance obligations are complied;
(d) the reporting obligations referred to in Articles 87 to 91 are fulfilled;
(e) in the case of investigational devices, the statement referred to in Section 4.1 of Chapter II of Annex XV is issued.